FASN-IN-1

CAS No. 1808260-84-5

FASN-IN-1( TVB-2460 )

Catalog No. M26213 CAS No. 1808260-84-5

FASN-IN-1 is a fatty acid synthase (FASN) inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 133 Get Quote
10MG 230 Get Quote
25MG 429 Get Quote
50MG 628 Get Quote
100MG 896 Get Quote
500MG 1791 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    FASN-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    FASN-IN-1 is a fatty acid synthase (FASN) inhibitor.
  • Description
    FASN-IN-1 is a fatty acid synthase (FASN) inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    TVB-2460
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Fatty Acid Synthase
  • Recptor
    NMDA receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1808260-84-5
  • Formula Weight
    395.54
  • Molecular Formula
    C18H25N3O3S2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (252.82 mM)
  • SMILES
    CC[C@H](C)C(=O)Nc1nc(cs1)-c1ccc(cc1)S(=O)(=O)N(CC)CC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Kondori NR, Paul P, Robbins JP, Liu K, Hildyard JCW, Wells DJ, de Belleroche JS. Focus on the Role of D-serine and D-amino Acid Oxidase in Amyotrophic Lateral Sclerosis/Motor Neuron Disease (ALS). Front Mol Biosci. 2018 Feb 13;5:8.
molnova catalog
related products
  • UCM05

    UCM05 (G28UCM) is a potent inhibitor of fatty acid synthase (FASN) with efficacy against HER2+ breast cancer xenografts, including cell lines resistant to anti-HER2 drugs .

  • FT113

    FT113 is a novel potent inhibitor of fatty acid synthase (fasn IC50 : 213 nM)and exhibits anti-cancer activity.

  • FASN-IN-2

    FASN-IN-2 is a Fatty Acid Synthase (FASN) inhibitor(IC50 of 0.052 μM and an EC50 of 0.072 μM),with potential antineoplastic activity.?TVB-2640 is an orally bioavailable fatty acid synthase (FASN) inhibitor, with potential antineoplastic activity.